Drugs for Encephalitis/encephalopathy, Mild, with Reversible Myelin Vacuolization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 71)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Remifentanil |
Approved |
Phase 4 |
|
132875-61-7 |
60815 |
Synonyms:
132539-07-2 (mono-hydrochloride)
132875-61-7
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
DEA No. 9739
GI 87084B
|
GI 87084X
GI87084B
L001266
LS-115982
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
MolPort-004-286-006
Remifentanil
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanil hydrochloride
Remifentanil monohydrochloride
Remifentanilo
Remifentanyl
Ultiva
Ultiva (TN)
UNII-P10582JYYK
|
|
2 |
|
Dexmedetomidine |
Approved, Vet_approved |
Phase 4 |
|
113775-47-6 |
68602 5311068 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
(+)-4-((S)-Α,2,3-trimethylbenzyl)imidazole
113775-47-6
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
Dexdor
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
DEXMEDETOMIDINE
|
Dexmédétomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidine hydrochloride
Dexmedetomidinum
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
MPV 1440
MPV-1440
NCGC00025347-01
Precedex
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
|
|
3 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
4 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
5 |
|
Anesthetics |
|
Phase 4 |
|
|
|
6 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
7 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
8 |
|
Narcotics |
|
Phase 4 |
|
|
|
9 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
11 |
|
Analgesics |
|
Phase 4 |
|
|
|
12 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
13 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
15 |
|
Benzocaine |
Approved, Investigational |
Phase 2, Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
16 |
|
tannic acid |
Approved |
Phase 2, Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
17 |
|
Interferon beta-1b |
Approved |
Phase 2, Phase 3 |
|
145155-23-3 |
|
Synonyms:
Betaseron
Fibroblast interferon
IFN-beta
Interferon beta 1b (recombinant)
|
Interferon beta precursor
Interferon beta-1b,recombinant
Interferon-beta-1b
Recombinant interferon beta-1b
|
|
18 |
|
Ritonavir |
Approved, Investigational |
Phase 2, Phase 3 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
19 |
|
Lopinavir |
Approved |
Phase 2, Phase 3 |
|
192725-17-0 |
92727 |
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
20 |
|
Meropenem |
Approved, Investigational |
Phase 3 |
|
96036-03-2, 119478-56-7 |
64778 441130 |
Synonyms:
(1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate
(1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate
(1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylIC ACID
(2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid
(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
96036-03-2
AB00514051
AB1004614
AC1L9ALL
Ambap119478-56-7
Antibiotic SM 7338
BIDD:GT0851
BPBio1_001334
BSPBio_001212
CHEBI:43968
CHEMBL127
CID441130
CPD000469184
D08185
HMS1571M14
HMS2051G08
HMS2090C05
|
ICI-194660
MEPM
Meronem
MERONEM
Meronem (TN)
Meropen
Meropenem
Meropenem (INN)
Meropenem anhydrous
Meropenemum
Merrem
Merrem i.v.
Merrem I.V. (TN)
MLS001401437
MolPort-006-709-417
NCGC00179259-01
Penem
Prestwick0_001106
Prestwick1_001106
Prestwick2_001106
Prestwick3_001106
Ronem
SAM001246650
SM-7338
SMR000469184
SPBio_003086
|
|
21 |
|
Avibactam |
Approved |
Phase 3 |
|
1192500-31-4 |
|
Synonyms:
|
22 |
|
Aztreonam |
Approved |
Phase 3 |
|
78110-38-0 |
5362041 5742832 |
Synonyms:
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
78110-38-0
AC1NX3U2
AC-4330
Ambap78110-38-0
Az threonam
Azactam
AZT
Azthreonam
Az-threonam
aztreonam
Aztreonam
Aztréonam
Aztreonam esteve brand
Aztreonam squibb brand
Aztreonamum
BIDD:GT0765
|
BPBio1_000121
BRD-K62607865-001-03-0
Bristol myers squibb brand OF aztreonam
Bristol-myers squibb brand OF aztreonam
BSPBio_000109
CHEBI:161680
CHEMBL158
CID5742832
Esteve brand OF aztreonam
HMS1568F11
HMS2090K09
MolPort-003-886-345
Monobactam
Monobactam, SQ 26776, Squibb 26776, Aztreonam
NCGC00179656-01
NSC646279
Prestwick_914
Prestwick2_000185
Prestwick3_000185
Primbactam
S1505_Selleck
Sanofi winthrop brand OF aztreonam
SQ-26776
Squibb brand OF aztreonam
Urobactam
|
|
23 |
|
Colistin |
Approved |
Phase 3 |
|
1066-17-7, 1264-72-8 |
5311054 |
Synonyms:
1066-17-7
AC1NSJWT
CID5311054
Colimycin
Colisticin
colistin
Colistin
Colistin sulfate
Colistin sulfate, nonsterile
Colistin sulphate
Colistina
Colistine
|
Colistinum
Coly-mycin
DB00803
Kolimycin
N-[(1S)-3-Amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-2,5,8,11,14,17,20-heptahydroxy-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclotricosa-1,4,7,10,13,16,19-heptaen-21-yl]-C-hydroxycarbonimidoyl}propyl]-C-hydroxycarbonimidoyl}-2-hydroxypropyl]-C-hydroxycarbonimidoyl}propyl]-5-methylheptanimidate
N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide
Polymyxin e
Polymyxin E
Polymyxin E. Sulfate
Sulfate, colistin
Totazina
|
|
24 |
|
Metronidazole |
Approved |
Phase 3 |
|
443-48-1 |
4173 |
Synonyms:
1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(Β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(Β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(β-oxyethyl)-2-methyl-5-nitroimidazole
1-(Β-oxyethyl)-2-methyl-5-nitroimidazole
1-Hydroxyethyl-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitro-1-imidazoleethanol
2-methyl-5-nitroimidazole-1-ethanol
2-Methyl-5-nitroimidazole-1-ethanol
443-48-1
46461_FLUKA
46461_RIEDEL
69198-10-3 (mono-hydrochloride)
99616-64-5
AB00052046
AC-10556
AC1L1HKS
AC1Q2P2Z
Acromona
AKOS000269646
Anagiardil
APMN
Apo-Metronidazole
Arilin
ARONIS24285
Atrivyl
BAS 02983617
BAY-5360
Bayer 5360
BCBcMAP01_000184
Bexon
BIDD:GT0107
Bio-0694
BPBio1_000004
BRD-K52020312-001-05-2
BRN 0611683
BSPBio_000002
BSPBio_002031
CAS-443-48-1
Caswell No. 579AA
CB-01-14 MMX
CCRIS 410
CHEBI:39845
CHEBI:6909
CHEMBL137
CID4173
Clont
Cont
CONT
CPD000058175
D00409
Danizol
DB00916
Deflamon
Deflamon-wirkstoff
Deflamon-Wirkstoff
DivK1c_000007
Efloran
EINECS 207-136-1
Elyzol
Entizol
EPA Pesticide Chemical Code 120401
Eumin
Flagemona
Flagesol
Flagil
Flagyl
Flagyl (TN)
Flagyl 375
Flagyl Er
Flagyl ER
Flagyl I.V.
Flagyl I.V. RTU
FLAGYL I.V. RTU IN PLASTIC CONTAINER
Flegyl
Florazole
Fossyol
Giatricol
Ginefla vir
Gineflavir
giniflavir
HMS1568A04
HMS1920N19
HMS2051G07
HMS2090B19
HMS2091F14
HMS500A09
HMS547C19
HSDB 3129
Hydrochloride, metronidazole
I14-0667
IDI1_000007
IDR-90105
KBio1_000007
KBio2_001515
KBio2_004083
KBio2_006651
KBio3_001531
KBioGR_000559
KBioSS_001515
Klion
Klont
LS-1264
M0924
M1547_SIGMA
M3761_FLUKA
M3761_SIGMA
M9036_SIGMA
Maybridge1_001999
Meronidal
Methronidazole
Methyl-5-nitroimidazole-1-ethanol
Metric
Metric 21
Metro Cream
Metro Gel
METRO I.V
Metro I.V.
Metro I.V. In Plastic Container
Metrocream
|
MetroCream
Metrodzhil
Metrogel
MetroGel
Metrogel-vaginal
Metrogel-Vaginal
MetroGel-Vaginal
Metrogel-vaginal (TN)
Metrogyl
Metrolag
Metrolotion
MetroLotion
Metrolyl
Metromidol
Metronidaz
Metronidazol
Metronidazol [INN-Spanish]
metronidazole
Metronidazole
Métronidazole
Metronidazole (JP15/USP/INN)
Metronidazole [USAN:INN:BAN:JAN]
Metronidazole benzoate
Metronidazole Benzoate
Metronidazole Hcl
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole in Plastic Container
Metronidazole monohydrochloride
Metronidazole Monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazole Phosphoester
METRONIDAZOLE USP
Metronidazolo
Metronidazolo [DCIT]
Metronidazolum
Metronidazolum [INN-Latin]
Metrotop
Metrozine
Metryl
Mexibol
Mexibol 'silanes'
MLS000028590
MLS000758286
MolPort-000-141-892
MolPort-002-502-101
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
NCGC00016446-01
NCGC00016446-02
NCGC00022059-03
NCGC00022059-04
NCGC00022059-05
NCIOpen2_000337
neo-Tric
Neo-Tric
Nida
NIDA
Nidagel
NINDS_000007
Noritate
Noritate (TN)
Noritic acid
Novonidazol
NSC 50364
NSC 69587
NSC50364
NSC-50364
NSC69587
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
Prestwick_334
Prestwick0_000081
Prestwick1_000081
Prestwick2_000081
Prestwick3_000081
Protostat
Rathimed
Rosased
RP 8823
RP-8823
S1907_Selleck
SAM001247010
Sanatrichom
Satric
SBB041018
SC 10295
SMP1_000189
SMR000058175
SPBio_000666
SPBio_001941
Spectrum_001035
SPECTRUM1500412
Spectrum2_000883
Spectrum3_000506
Spectrum4_000060
Spectrum5_001289
STK177359
Takimetol
Trichazol
Trichex
Tricho cordes
Tricho Cordes
Trichocide
Tricho-gynaedron
Tricho-Gynaedron
Trichomol
Trichomonacid 'pharmachim'
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
UNII-140QMO216E
Vagilen
Vagimid
Vandazole
Vertisal
Wagitran
WLN: T5N CNJ A2Q B1 ENW
WLN: T5N CNJA2Q B1 ENW
WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW
Zadstat
ZERO/004064
Zidoval
ZINC00113442
|
|
25 |
|
Lenalidomide |
Approved |
Phase 3 |
|
191732-72-6 |
216326 |
Synonyms:
191732-72-6
1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
346670-73-3
443912-14-9
AC1L50II
AC-914
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CDC 501
CDC-501
CDC-5013
Celgene brand of lenalidomide
Celgene brand OF lenalidomide
CHEMBL848
CID216326
D04687
|
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMiD3
IMiD3 cpd
IMiD3 CPD
IMID-5013
Lenalidomida
lenalidomide
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
LS-184040
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
|
|
26 |
|
Nafamostat |
Investigational |
Phase 2, Phase 3 |
|
81525-10-2 |
|
Synonyms:
|
p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine
|
|
27 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Anti-HIV Agents |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Interferon-beta |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
interferons |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Adjuvants, Immunologic |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Anti-Retroviral Agents |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Antiviral Agents |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Anti-Inflammatory Agents |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Complement System Proteins |
|
Phase 2, Phase 3 |
|
|
|
40 |
|
Anti-Infective Agents, Local |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Trypsin Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
44 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
45 |
|
Hematinics |
|
Phase 3 |
|
|
|
46 |
|
Epoetin alfa |
|
Phase 3 |
|
113427-24-0 |
|
47 |
|
Zoledronic Acid |
Approved |
Phase 2 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
ácido zoledrónico
Aclasta
AKOS005145739
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42446
CGP 42'446
CGP 42446A
CGP-42446
CGP-42'446
CHEBI:46557
CHEMBL924
CID68740
|
D08689
DB00399
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
Novartis brand of zoledronic acid
Novartis brand OF zoledronic acid
NSC721517
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
Zol
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zoledronic acid anhydrous
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
|
|
48 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
49 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citrate anhydrous
Citretten
Citric acid anhydrous
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
Uro-trainer
|
|
50 |
|
Acyline |
Investigational |
Phase 1, Phase 2 |
|
170157-13-8 |
|
Interventional clinical trials:
(show all 31)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery |
Recruiting |
NCT03283150 |
Phase 4 |
Remifentanil;Propofol;Dexmedetomidine |
2 |
Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery Disease With an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy |
Withdrawn |
NCT02723981 |
Phase 4 |
Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran |
3 |
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial |
Completed |
NCT02845843 |
Phase 2, Phase 3 |
Combination of Lopinavir /Ritonavir and Interferon beta-1b;Placebo |
4 |
A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS |
Recruiting |
NCT03329092 |
Phase 3 |
ATM-AVI;MTZ;MER;COL |
5 |
Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19 |
Recruiting |
NCT04473053 |
Phase 2, Phase 3 |
Nafamostat Mesilate;TD139 |
6 |
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia |
Active, not recruiting |
NCT00843882 |
Phase 3 |
Lenalidomide |
7 |
Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18 |
Unknown status |
NCT02572336 |
Phase 2 |
THR-18;Placebo;Tissue Plasminogen Activator (tPA) |
8 |
Double-blind, Placebo-controlled, Escalating Single-dose, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of THR-18 in Subjects With Acute Ischemic Stroke and Treated With tPA |
Completed |
NCT01957774 |
Phase 2 |
THR-18;Placebo |
9 |
Oral Administration of the GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02) |
Completed |
NCT00603187 |
Phase 1, Phase 2 |
Acyline |
10 |
A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients |
Completed |
NCT00636740 |
Phase 2 |
Zoledronic Acid 20mg Tablets;Zoledronic Acid;Zoledronic Acid 20mg Tablets |
11 |
Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac", a Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers |
Recruiting |
NCT04130594 |
Phase 1, Phase 2 |
|
12 |
Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac-Combi", a Combined Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers |
Recruiting |
NCT04128059 |
Phase 1, Phase 2 |
BVRS-GamVac-Combi |
13 |
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers |
Not yet recruiting |
NCT04588428 |
Phase 2 |
INO-4700;Placebo |
14 |
Anti-MERS-COV Convalescent Plasma Therapy |
Withdrawn |
NCT02190799 |
Phase 2 |
|
15 |
A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults |
Completed |
NCT03301090 |
Phase 1 |
|
16 |
A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers |
Completed |
NCT04170829 |
Phase 1 |
|
17 |
Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure |
Completed |
NCT02627378 |
Phase 1 |
|
18 |
An Open, Single Center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S |
Completed |
NCT03615911 |
Phase 1 |
|
19 |
A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults |
Completed |
NCT02788188 |
Phase 1 |
|
20 |
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers |
Recruiting |
NCT03399578 |
Phase 1 |
|
21 |
A Phase 1a/1b Study of OPT101 in Healthy Volunteers |
Recruiting |
NCT04589403 |
Phase 1 |
OPT101 |
22 |
A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects |
Not yet recruiting |
NCT04119440 |
Phase 1 |
|
23 |
Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient |
Completed |
NCT02497885 |
|
|
24 |
The Merendino Procedure for Benign or Early Malignant Lesions of the Distal Esophagus/Gastroesophageal Junction is Feasible, Safe and Provides Good QoL |
Completed |
NCT02855333 |
|
|
25 |
Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples |
Completed |
NCT01139333 |
|
|
26 |
Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients by Assessment of Gliadin 33-mer Equivalent Epitopes in Feces |
Completed |
NCT01478867 |
|
|
27 |
Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea |
Completed |
NCT02605109 |
|
|
28 |
Incidence of Iatrogenic Diseases on Toulon-La Seyne Sur Mer Hospital Emergency Consultations During Summer 2018 |
Completed |
NCT03960398 |
|
Iatrogenic disease impact on emergency consultations |
29 |
Badanie Kliniczne oceniające bezpieczeństwo i skuteczność Stosowania stentów Szyjnych MER® w Rewaskularyzacji tętnic Szyjnych. |
Completed |
NCT03133429 |
|
|
30 |
Detecting Soluble MER Levels After Myocardial Ischemia and Reperfusion Injury in Pediatric Patients |
Active, not recruiting |
NCT04322630 |
|
|
31 |
A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors |
Terminated |
NCT03454243 |
Early Phase 1 |
RXDX-106 |
Search
NIH Clinical Center
for Encephalitis/encephalopathy, Mild, with Reversible Myelin Vacuolization
|